Cardiovascular Safety Profile of Dapoxetine during the Premarketing Evaluation

@inproceedings{Kowey2011CardiovascularSP,
  title={Cardiovascular Safety Profile of Dapoxetine during the Premarketing Evaluation},
  author={Peter Russell Kowey and Ramagopal V. Mudumbi and Joseph W. Aquilina and Peter M Dibattiste},
  booktitle={Drugs in R&D},
  year={2011}
}
The cardiovascular safety profile of dapoxetine, a novel selective serotonin reuptake inhibitor (SSRI) developed as an on-demand oral treatment for premature ejaculation (PE) in men, is evaluated. The cardiovascular assessment of dapoxetine was conducted throughout all stages of drug development, with findings from preclinical safety pharmacology studies, phase I clinical pharmacology studies investigating the effect of dapoxetine on QT/corrected QT (QTc) intervals in healthy men, and phase III… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Similar Papers

Loading similar papers…